These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 29685424)
1. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm. Bair SM; Mato A; Svoboda J Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424 [TBL] [Abstract][Full Text] [Related]
2. Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective. Iqbal M; Kharfan-Dabaja MA Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):95-103. PubMed ID: 32603659 [TBL] [Abstract][Full Text] [Related]
3. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Grosser R; Cherkassky L; Chintala N; Adusumilli PS Cancer Cell; 2019 Nov; 36(5):471-482. PubMed ID: 31715131 [TBL] [Abstract][Full Text] [Related]
5. Current and future immunotherapeutic approaches in Hodgkin lymphoma. Bröckelmann PJ; Borchmann P; Engert A Leuk Lymphoma; 2016 Sep; 57(9):2014-24. PubMed ID: 27243940 [TBL] [Abstract][Full Text] [Related]
6. Development of adaptive immune effector therapies in solid tumors. Comoli P; Chabannon C; Koehl U; Lanza F; Urbano-Ispizua A; Hudecek M; Ruggeri A; Secondino S; Bonini C; Pedrazzoli P; Ann Oncol; 2019 Nov; 30(11):1740-1750. PubMed ID: 31435646 [TBL] [Abstract][Full Text] [Related]
7. The emerging role of immune checkpoint based approaches in AML and MDS. Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300 [TBL] [Abstract][Full Text] [Related]
8. Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. Calabretta E; d'Amore F; Carlo-Stella C Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31694167 [TBL] [Abstract][Full Text] [Related]
9. Clinical development of immunotherapy for prostate cancer. Noguchi M; Koga N; Igawa T; Itoh K Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142 [TBL] [Abstract][Full Text] [Related]
10. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. Epperla N; Hamadani M Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):247-253. PubMed ID: 34889401 [TBL] [Abstract][Full Text] [Related]
11. Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma. Choi Y; Diefenbach CS Curr Oncol Rep; 2020 Jan; 22(1):6. PubMed ID: 31981025 [TBL] [Abstract][Full Text] [Related]
12. Drug resistance and new therapies in colorectal cancer. Van der Jeught K; Xu HC; Li YJ; Lu XB; Ji G World J Gastroenterol; 2018 Sep; 24(34):3834-3848. PubMed ID: 30228778 [TBL] [Abstract][Full Text] [Related]
14. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide. Paulson KG; Bhatia S J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. Pianko MJ; Moskowitz AJ; Lesokhin AM Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972 [TBL] [Abstract][Full Text] [Related]
16. Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies. Moehler M; Göpfert K; Lenz HJ Oncol Res Treat; 2018; 41(5):313-315. PubMed ID: 29705792 [TBL] [Abstract][Full Text] [Related]
17. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458 [TBL] [Abstract][Full Text] [Related]
18. Immune and Cell Therapy in Non-Hodgkin Lymphoma. Merryman RW; Houot R; Armand P; Jacobson C Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460 [TBL] [Abstract][Full Text] [Related]
19. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. Georganaki M; van Hooren L; Dimberg A Front Immunol; 2018; 9():3081. PubMed ID: 30627131 [TBL] [Abstract][Full Text] [Related]
20. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond. Su CT; Ye JC J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]